REGN

Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The article questions whether investors are paying too much for Regeneron compared to its competitors, but no specific data or analysis is provided.

TD Cowen keeps a Buy rating on Regeneron and lifts its target price to $980 from $960, indicating a more optimistic view of the company’s future performance.

Longleaf Partners, managed by Southeastern Asset Management, released its third-quarter 2026 investor letter for its “Partners Fund”. The letter can be downloaded here. Coming into this year, the Fund’s three-year annualized returns were at 11.7%, but recent performance, particularly this year and in Q3, has raised concerns about the investment strategy.

Regeneron Pharmaceuticals (REGN) stock returned 37.9% in the year to October 16, 2026. This easily outpaced the 16.2% gain for the S&P 500 and left investors looking at a higher price. The underlying business has grown faster lately, yet its operating margin has slipped in each of the past three years.

Piper Sandler maintains an Overweight stance on Regeneron and raises its target price to $865 from $854, suggesting confidence in the stock’s upside.

The piece suggests Regeneron’s real value may lie in the profit share from its Dupixent drug, hinting at ongoing growth potential beyond its flagship product.

The EMA’s CHMP has given a positive opinion to approve a less frequent dosing schedule for Libtayo across all approved indications, potentially easing treatment burden.